Last reviewed · How we verify

Radium-223 chloride — Competitive Intelligence Brief

Radium-223 chloride (Radium-223 chloride) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Targeted alpha therapy; radiopharmaceutical. Area: Oncology.

phase 3 Targeted alpha therapy; radiopharmaceutical Bone matrix (calcium-mimetic); osteoblastic lesions Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Radium-223 chloride (Radium-223 chloride) — Amsterdam UMC, location VUmc. Radium-223 is an alpha-emitting radioisotope that mimics calcium and selectively targets bone metastases, delivering high-energy alpha particles directly to cancer cells in bone.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Radium-223 chloride TARGET Radium-223 chloride Amsterdam UMC, location VUmc phase 3 Targeted alpha therapy; radiopharmaceutical Bone matrix (calcium-mimetic); osteoblastic lesions

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Targeted alpha therapy; radiopharmaceutical class)

  1. Amsterdam UMC, location VUmc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Radium-223 chloride — Competitive Intelligence Brief. https://druglandscape.com/ci/radium-223-chloride. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: